Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 5Phase 3 4

Status

Recruiting 5Completed 4Active not recruiting 3Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4Lymphoid 1

Conditions

Multiple Myeloma 4Lymphoma 1

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Completed × elotuzumab × Clear all
NCT02726581 2023-03-27

CheckMate 602

Bristol-Myers Squibb

Phase 3 Completed
170 enrolled 16 charts
Plasma cell

Multiple Myeloma

NCT01335399 2022-09-30

ELOQUENT - 1

Bristol-Myers Squibb

Phase 3 Completed
748 enrolled 15 charts
Plasma cell

Multiple Myeloma

NCT01239797 2022-06-01

ELOQUENT - 2

Bristol-Myers Squibb

Phase 3 Completed
646 enrolled 16 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT02495922 2021-09-10

GMMG-HD6

University of Heidelberg Medical Center

Phase 3 Completed
564 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡